Market-Changing Launches Expected In 2020

7 Product Launches To Watch Out For

We might only be halfway through 2019, but In Vivo is taking in the long view and exploring some of the market-altering new drugs on the horizon that are expected to win approval and experience first launches at the opening of the next decade.

In a recent report, Informa Intelligence’s Biomedtracker highlighted various products that are anticipated to enter the US market in 2020 for the first time or in new indications. These therapies represent novel drug classes, large market opportunities and treatments that are predicted to heavily impact the current standard of care for certain indications.

Overall, Biomedtracker believes that more than 50 candidate medicines, across 15 broad therapeutic categories and involving more than 60 companies,...

More from Market Intelligence

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.